← Neurocrine Biosciences overview

Neurocrine Biosciences vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Neurocrine Biosciences Inc (NBIX)

Q3 2026
▲3▼1

Neurocrine's Q3: Strong Sales, Pipeline Progress, But Cash Drops

  • Strong Q2 results and raised guidance Neurocrine reported Q2 revenue of $959 million, up 39%, and adjusted EPS of $2.85. Management raised full-year guidance for its key drug INGREZZA to $2.825–$2.875 billion, signaling confidence in continued growth.

    This shows the core business is performing well and management expects further growth, which likely boosted investor confidence.

  • CRENESSITY's rapid growth and expansion CRENESSITY sales surged 247% in Q2 and 400% in the first half. With only 15% of diagnosed patients treated, there's ample room to grow. The drug also expanded into younger children, broadening its market.

    This highlights a major growth driver with significant untapped potential, which could drive future revenue.

  • Pipeline advancements and analyst optimism The obesity drug NBIP-1968 entered Phase 1 testing, and analysts turned bullish, citing a Strong Buy rating and a cheap valuation of about 17 times forward earnings. This suggests upside potential.

    Pipeline progress and positive analyst sentiment can attract investors and support the stock price.

  • Cash decline and competitive threats Cash fell from $2.5 billion to $482 million after the $2.9 billion Soleno acquisition. Additionally, Vertex acquired a rival CAH drug, increasing competition, and pipeline programs remain years from approval.

    These factors raise financial and competitive risks that could weigh on the stock.

August 2026
▲3

Neurocrine's Ingrezza and Crenessity Surge, Obesity Pipeline Advances

  • Q2 Beat and Raised Ingrezza Guidance Neurocrine beat second-quarter expectations with revenue up 39% to $959 million and adjusted earnings of $2.85 per share. Management raised 2026 Ingrezza sales guidance to $2.825-$2.875 billion, signaling confidence in its core drug and lifting investor expectations.

    This is the period's biggest financial catalyst, directly boosting earnings outlook and stock sentiment.

  • Crenessity Sales Surge 400% Crenessity, launched in December 2024 for a rare hormonal disorder, generated $337 million in the first half of 2026, up 400% year over year. Its prescriber base nearly tripled, with only 15% of diagnosed patients on the drug, leaving room for more growth.

    Shows a second drug becoming a major growth driver, reducing reliance on Ingrezza and supporting higher valuation.

  • Obesity Drug Enters Phase 1 Neurocrine started a Phase 1 trial of NBIP-'1968, an experimental obesity drug that targets three hormone receptors. Early-stage testing is a first step toward a potentially large new market, though years of testing remain before any approval.

    Highlights pipeline expansion into the hot obesity space, which can add long-term growth potential.

  • Leadership Changes and Cash Burn Neurocrine appointed a new Chief Business Officer and reappointed its former Chief Medical Officer, bringing continuity and deal-making focus. However, cash fell from $2.5 billion to $482 million after the $2.9 billion Soleno acquisition, and competition looms from Vertex's purchase of a rival CAH drug.

    Balances positive management moves against financial and competitive risks that could pressure the stock.

Latest
▲3

Neurocrine's Ingrezza and Crenessity Surge, Obesity Pipeline Advances

  • Q2 Beat and Raised Ingrezza Guidance Neurocrine beat second-quarter expectations with revenue up 39% to $959 million and adjusted earnings of $2.85 per share. Management raised 2026 Ingrezza sales guidance to $2.825-$2.875 billion, signaling confidence in its core drug and lifting investor expectations.

    This is the period's biggest financial catalyst, directly boosting earnings outlook and stock sentiment.

  • Crenessity Sales Surge 400% Crenessity, launched in December 2024 for a rare hormonal disorder, generated $337 million in the first half of 2026, up 400% year over year. Its prescriber base nearly tripled, with only 15% of diagnosed patients on the drug, leaving room for more growth.

    Shows a second drug becoming a major growth driver, reducing reliance on Ingrezza and supporting higher valuation.

  • Obesity Drug Enters Phase 1 Neurocrine started a Phase 1 trial of NBIP-'1968, an experimental obesity drug that targets three hormone receptors. Early-stage testing is a first step toward a potentially large new market, though years of testing remain before any approval.

    Highlights pipeline expansion into the hot obesity space, which can add long-term growth potential.

  • Leadership Changes and Cash Burn Neurocrine appointed a new Chief Business Officer and reappointed its former Chief Medical Officer, bringing continuity and deal-making focus. However, cash fell from $2.5 billion to $482 million after the $2.9 billion Soleno acquisition, and competition looms from Vertex's purchase of a rival CAH drug.

    Balances positive management moves against financial and competitive risks that could pressure the stock.

July 2026
▲4

Neurocrine's CRENESSITY launch accelerates as Q2 revenue jumps 39%

  • CRENESSITY data broadens and launch surges New ENDO 2026 data showed CRENESSITY improved hormone control, heart and bone health in CAH, and Q2 sales then jumped 247% to $184 million. This tells investors the newest drug is becoming a real second growth engine, not just a promise.

    It is the core new growth story behind the stock's move.

  • Q2 results beat and INGREZZA guidance raised Second-quarter revenue rose 39% to $959 million and adjusted earnings jumped to $2.85 a share. Management raised full-year INGREZZA sales guidance to $2.825-$2.875 billion, signaling the flagship drug keeps growing faster than expected.

    The earnings beat and raised guidance are the period's biggest fresh price driver.

  • Crinecerfont expands toward younger children Neurocrine started a Phase 2 trial of crinecerfont in children aged 3 months to under 4, aiming to widen CRENESSITY's approved use. A larger patient pool means more future sales, though approval is still years away.

    It is a new pipeline expansion that supports long-term growth expectations.

  • Analyst estimates and valuation draw buyers Analysts raised earnings estimates sharply, earning a Zacks Strong Buy, while the stock trades near 17 times forward earnings versus an industry average above 90. Cheap valuation plus rising estimates makes the shares attractive to new investors.

    It explains the money-flow and sentiment side of the rally.

▲4

Neurocrine's CRENESSITY launch accelerates as Q2 revenue jumps 39%

  • CRENESSITY data broadens and launch surges New ENDO 2026 data showed CRENESSITY improved hormone control, heart and bone health in CAH, and Q2 sales then jumped 247% to $184 million. This tells investors the newest drug is becoming a real second growth engine, not just a promise.

    It is the core new growth story behind the stock's move.

  • Q2 results beat and INGREZZA guidance raised Second-quarter revenue rose 39% to $959 million and adjusted earnings jumped to $2.85 a share. Management raised full-year INGREZZA sales guidance to $2.825-$2.875 billion, signaling the flagship drug keeps growing faster than expected.

    The earnings beat and raised guidance are the period's biggest fresh price driver.

  • Crinecerfont expands toward younger children Neurocrine started a Phase 2 trial of crinecerfont in children aged 3 months to under 4, aiming to widen CRENESSITY's approved use. A larger patient pool means more future sales, though approval is still years away.

    It is a new pipeline expansion that supports long-term growth expectations.

  • Analyst estimates and valuation draw buyers Analysts raised earnings estimates sharply, earning a Zacks Strong Buy, while the stock trades near 17 times forward earnings versus an industry average above 90. Cheap valuation plus rising estimates makes the shares attractive to new investors.

    It explains the money-flow and sentiment side of the rally.

Regeneron Pharmaceuticals Inc (REGN)

Q3 2026
▲2▼2

Regeneron's Q3: pipeline wins, Sanofi deal, but melanoma setback

  • Strong Q2 results and pipeline progress Regeneron reported Q2 revenue up 17% to $4.29 billion, received FDA priority review for cemdisiran in myasthenia gravis, and won approval for Pasatru in FOP disease. These advances support future growth.

    These positive developments drove investor optimism and supported the stock.

  • Expanded Sanofi deal and obesity drug data Regeneron expanded its Sanofi partnership with $1 billion upfront and four pipeline therapies. Its obesity drug trevogrumab preserved about 70% of muscle loss in a Phase 2 trial, showing promise in a large market.

    The deal and trial data are new positive catalysts for Regeneron's growth outlook.

  • Failed melanoma trial and lawsuits A failed melanoma trial led to class-action lawsuits and an $11 billion market-value loss. This setback raised concerns about pipeline execution and weighed on the stock.

    This was a major negative event that hurt investor confidence and the share price.

  • Eylea competition and Sanofi deal disappointment Eylea faces biosimilar and competitive threats, notably Kodiak's less-frequent-dosing eye drug. The Sanofi deal left Dupixent profit-sharing unchanged, disappointing some investors and briefly pressuring shares.

    These competitive and deal-related concerns created headwinds for the stock.

August 2026
▲2▼1

Regeneron's strong Q2 and pipeline wins offset by legal and competitive risks

  • Strong Q2 earnings and margin improvement Regeneron beat Q2 estimates with revenue up 17% to $4.29 billion, driven by Dupixent and high-dose Eylea. Repaying the Sanofi Development Balance should improve margins, and buybacks and dividends support shareholder value.

    This point explains the positive financial performance that drove the stock during the period.

  • Pipeline progress and new Sanofi deal FDA approval of Pasatru for rare FOP disease validates Regeneron's drug platform. A new Sanofi deal adds $1 billion upfront and four pipeline therapies, strengthening the pipeline and providing external validation.

    This point highlights key pipeline and partnership developments that boosted investor sentiment.

  • Pipeline uncertainty and Eylea competition Mixed melanoma trial results and increasing competition for Eylea add pipeline uncertainty. These factors offset strong commercial performance and contribute to a balanced but cautious outlook.

    This point explains the competitive and pipeline challenges that acted as a counterweight to positive developments.

Latest
▲2▼2

Regeneron's Sanofi deal and pipeline progress offset by Eylea competition and lawsuits

  • Sanofi deal expands pipeline with $1B upfront Regeneron and Sanofi agreed to jointly develop four long-acting immunology therapies, led by REGN20423, in a deal worth up to $8 billion including $1 billion upfront. This brings cash and pipeline growth, supporting future revenue and the stock.

    This is a major new partnership that directly boosts Regeneron's pipeline and cash, a key positive driver.

  • Securities class action lawsuits weigh on sentiment Multiple law firms filed class actions alleging Regeneron made false statements about its Fianlimab-Libtayo trial, causing investor losses. The legal uncertainty and potential reputational damage pressure the stock, though the company denies wrongdoing.

    These lawsuits are a new negative overhang that could affect investor confidence and lead to financial penalties.

  • Mixed melanoma trial results lead to pullback Regeneron's melanoma drug trial produced mixed results, causing shares to give back some gains. This setback raises doubts about the drug's potential and adds to pipeline uncertainty, weighing on the stock.

    This is a new clinical setback that directly impacts Regeneron's oncology pipeline and investor expectations.

  • Buybacks and dividend support shareholder value Regeneron confirmed its quarterly dividend, updated on share repurchases, and reported Q2 results. With the stock trading below fair value estimates, these capital returns and pipeline progress support the shares.

    This shows management's commitment to returning cash and the stock's valuation appeal, a positive for investors.

September 2026
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

July 2026
▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.